Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodeBreaK 202 first-line sotorasib plus platinum doublet chemotherapy versus pembrolizumab plus platinum doublet chemotherapy in PD-L1-negative KRAS G12C-positive non-squamous NSCLC
CTR20240724Phase 3Active
- Sponsor
- Amgen
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing sotorasib plus platinum doublet chemotherapy with pembrolizumab plus platinum doublet chemotherapy (2 arms). Primary endpoint: Progression-free survival. Started Jul 2024; status: active.
02
Drugs
sotorasibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20240724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240724.